MX2009004426A - Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. - Google Patents

Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.

Info

Publication number
MX2009004426A
MX2009004426A MX2009004426A MX2009004426A MX2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A MX 2009004426 A MX2009004426 A MX 2009004426A
Authority
MX
Mexico
Prior art keywords
alk
diaminopyrimidine
fused bicyclic
met inhibitors
bicyclic derivatives
Prior art date
Application number
MX2009004426A
Other languages
English (en)
Inventor
Benjamin J Dugan
James L Diebold
Diane E Gingrich
Theodore L Underiner
Rabindranath Tripathy
Koc-Kan Ho
Jay P Theroff
Linda Weinberg
Keith S Learn
Jason C Wagner
Gregory J Wells
Gulzar Ahmed
Adolph Bohnstedt
Henry Joseph Breslin
Jason Burke
Matthew A Curry
Bruce Dorsey
Daming Feng
Tao Guo
Joseph G Lisko
Rong-Qiang Liu
Eugen F Mesaros
Karen Milkiewicz
Gregory R Ott
Jonathan Parrish
Tho V Thieu
Ming You
Graig A Zificsak
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39050187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009004426(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2009004426A publication Critical patent/MX2009004426A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La presente invención proporciona un compuest.o de la fórmula I ó II (ver fórmulas) o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4, R5, A1, A2, A3, A4, y A5, son como se define en la presente. Los compuestos de la fórmula I ó II tienen actividad inhibidora ALK y/o c-Met, y se pueden usar para tratar trastornos proliferativos.
MX2009004426A 2006-10-23 2007-10-23 Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. MX2009004426A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85356206P 2006-10-23 2006-10-23
PCT/US2007/022496 WO2008051547A1 (en) 2006-10-23 2007-10-23 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors

Publications (1)

Publication Number Publication Date
MX2009004426A true MX2009004426A (es) 2009-08-12

Family

ID=39050187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004426A MX2009004426A (es) 2006-10-23 2007-10-23 Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.

Country Status (15)

Country Link
US (2) US8148391B2 (es)
EP (2) EP2222647B1 (es)
JP (1) JP5512274B2 (es)
CN (1) CN101535276B (es)
AR (1) AR063527A1 (es)
AU (1) AU2007309427B2 (es)
CA (1) CA2669111C (es)
CL (1) CL2007003049A1 (es)
ES (2) ES2633318T3 (es)
HK (1) HK1147748A1 (es)
IL (1) IL198150A (es)
MX (1) MX2009004426A (es)
NZ (1) NZ576425A (es)
TW (1) TWI432427B (es)
WO (1) WO2008051547A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US8440681B2 (en) 2007-08-28 2013-05-14 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
CA2720946C (en) 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
PE20110711A1 (es) 2008-11-19 2011-10-11 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
EP2373172B1 (en) 2008-12-03 2013-07-17 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
WO2010128659A1 (ja) 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
WO2010132423A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2440534A2 (en) * 2009-06-10 2012-04-18 Cellzome Limited Pyrimidine derivatives as zap-70 inhibitors
LT3345903T (lt) * 2009-06-10 2019-12-10 Chugai Pharmaceutical Co Ltd Tetracikliniai junginiai
EP2464645B1 (en) * 2009-07-27 2017-07-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
AU2010317842A1 (en) * 2009-11-16 2012-07-12 Mellitech [1,5]-diazocin derivatives
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CA2808210C (en) * 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
JP5006987B2 (ja) * 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
NZ716420A (en) 2011-05-10 2017-05-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
AU2012340555B2 (en) 2011-11-23 2016-10-20 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
ES2628438T3 (es) * 2011-11-29 2017-08-02 Genentech, Inc. Derivados de aminopirimidina como moduladores de LRRK2
MY177290A (en) * 2012-03-06 2020-09-10 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN103664903A (zh) * 2012-09-04 2014-03-26 中国科学院上海药物研究所 苯氮卓类化合物及其制备方法和用途
ES2692664T3 (es) 2012-09-25 2018-12-04 Chugai Seiyaku Kabushiki Kaisha Inhibidor de RET
WO2014071832A1 (en) * 2012-11-06 2014-05-15 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
WO2014121654A1 (zh) * 2013-02-05 2014-08-14 山东轩竹医药科技有限公司 四并环激酶抑制剂
CN104994879A (zh) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 治疗癌症和预防药物抗性的方法
KR102334260B1 (ko) 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA2914310A1 (en) 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
WO2015038868A1 (en) * 2013-09-13 2015-03-19 Cephalon, Inc. Fused bicyclic 2,4-diaminopyrimidine derivatives
KR101656382B1 (ko) 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
KR20160142383A (ko) 2014-04-25 2016-12-12 추가이 세이야쿠 가부시키가이샤 4환성 화합물의 신규 결정
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
AU2015266453C1 (en) * 2014-05-30 2018-09-13 Shanghai Emerald Wellcares Pharmaceutical Co., Ltd Alk kinase inhibitor, and preparation method and use thereof
CN106459007B (zh) * 2014-06-17 2020-02-28 韩国化学研究院 嘧啶-2，4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途
KR101633722B1 (ko) 2014-10-08 2016-06-28 한국화학연구원 4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
WO2016087370A1 (en) * 2014-12-01 2016-06-09 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
WO2016100711A1 (en) * 2014-12-18 2016-06-23 The Broad Institute, Inc. Modulators of hepatic lipoprotein metabolism
TWI752901B (zh) 2015-01-16 2022-01-21 日商中外製藥股份有限公司 合併用醫藥
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101653571B1 (ko) 2015-04-22 2016-09-05 한국화학연구원 4-(2-아미노-테트라하이드로나프탈렌닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN105400143B (zh) * 2015-12-11 2017-10-03 广州欣凯化工科技有限公司 一种木制品缝隙的修补组合物
MX2018008653A (es) 2016-01-15 2018-12-10 Pfizer Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
AU2018308038B2 (en) 2017-07-28 2022-02-03 Yuhan Corporation Improved process for preparing aminopyrimidine derivatives
JP2020531574A (ja) * 2017-08-18 2020-11-05 北京韓美薬品有限公司Ｂｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍ． Ｃｏ．， Ｌｔｄ． 化合物、その医薬組成物及びその使用及び応用
CN110240545B (zh) * 2018-03-08 2022-04-26 迈克斯(如东)化工有限公司 一种2-(5-氟-2,4-二硝基苯氧)乙酸的制备方法
TWI674931B (zh) * 2018-03-13 2019-10-21 川尚股份有限公司 污染混合物的處理方法
JP7149089B2 (ja) * 2018-03-26 2022-10-06 株式会社日本触媒 含窒素複素環化合物およびスクアリリウム化合物の製造方法
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
SG11202100983XA (en) 2018-09-04 2021-03-30 Chugai Pharmaceutical Co Ltd Method of producing tetracyclic compound
CN109632773B (zh) * 2019-01-08 2021-11-12 贵州大学 一种二氢硫辛酸琥珀酰转移酶抑制剂的筛选方法
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021080980A1 (en) * 2019-10-22 2021-04-29 Alphala Co., Ltd. Pyrimidine amide compounds and use thereof
CN110950797A (zh) * 2019-12-06 2020-04-03 丽水绿氟科技有限公司 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法
CA3169286A1 (en) * 2020-02-25 2021-09-02 Dana-Farber Cancer Institute, Inc. Potent and selective degraders of alk
CN115667226A (zh) * 2020-04-14 2023-01-31 齐鲁制药有限公司 作为egfr抑制剂的三环化合物
EP4163278A1 (en) * 2020-05-29 2023-04-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Pyrimidine compound as axl inhibitor
CN112213428A (zh) * 2020-10-13 2021-01-12 辽宁科技大学 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法
EP4274829A1 (en) * 2021-01-07 2023-11-15 Ontario Institute for Cancer Research (OICR) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
CN116768888A (zh) * 2021-03-23 2023-09-19 杭州阿诺生物医药科技有限公司 Hpk1激酶抑制剂化合物
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115838383A (zh) * 2021-09-22 2023-03-24 南京正大天晴制药有限公司 作为axl抑制剂的苯并环庚烷类化合物
WO2023061434A1 (zh) * 2021-10-14 2023-04-20 齐鲁制药有限公司 一种三环化合物的用途
CN114133360A (zh) * 2021-11-30 2022-03-04 南京工业大学 一种含氟苯并[d]-1,3-氧氮杂卓化合物及其合成方法
CN114539104A (zh) * 2022-03-09 2022-05-27 常州佳德医药科技有限公司 一种艾拉莫德中间体的制备方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297910A1 (en) 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
EP0945443B9 (en) * 1998-03-27 2003-08-13 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
MEP13408A (en) 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
AU2002316421B2 (en) 2001-06-26 2008-05-15 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-ALPHA expression
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
ATE389638T1 (de) 2001-11-01 2008-04-15 Janssen Pharmaceutica Nv Aminobenzamidderivate als inhibitoren der glycogensynthasekinase-3-
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002367172A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60332433D1 (de) 2002-03-15 2010-06-17 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
WO2003078426A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
DE60332604D1 (de) 2002-03-15 2010-07-01 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
ES2373226T3 (es) * 2002-06-28 2012-02-01 Astellas Pharma Inc. Derivado de diaminopirimidincarboxamida.
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
DK2476667T3 (da) 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2529622A1 (en) 2003-07-02 2005-01-20 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
NZ585188A (en) * 2003-08-15 2011-09-30 Novartis Ag 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
WO2005026130A1 (en) 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP2609919A3 (en) 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
US7144889B2 (en) 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
EP1694652A1 (en) 2003-12-19 2006-08-30 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
US7435823B2 (en) 2004-01-23 2008-10-14 Amgen Inc. Compounds and methods of use
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0507834A (pt) 2004-02-23 2007-07-10 Sugen Inc método para tratar o crescimento celular anormal usando inibidores de c-met e de m-tor
US7973061B2 (en) 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
EP1758887A1 (en) 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566332A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566531A1 (en) 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
CA2590110C (en) 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007006926A2 (fr) 2005-07-11 2007-01-18 Sanofi-Aventis Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2007028445A1 (en) 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1966207A2 (en) 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
EP1979329A2 (en) 2006-01-30 2008-10-15 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
KR101149295B1 (ko) 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물

Also Published As

Publication number Publication date
CA2669111A1 (en) 2008-05-02
EP2684874B1 (en) 2017-05-17
US8148391B2 (en) 2012-04-03
ES2555803T3 (es) 2016-01-08
AU2007309427B2 (en) 2013-02-28
TWI432427B (zh) 2014-04-01
CA2669111C (en) 2016-04-12
NZ576425A (en) 2012-04-27
AU2007309427A1 (en) 2008-05-02
US8552186B2 (en) 2013-10-08
AR063527A1 (es) 2009-01-28
EP2222647A1 (en) 2010-09-01
IL198150A0 (en) 2009-12-24
CN101535276A (zh) 2009-09-16
CN101535276B (zh) 2013-08-28
US20090221555A1 (en) 2009-09-03
JP5512274B2 (ja) 2014-06-04
TW200833686A (en) 2008-08-16
EP2222647B1 (en) 2015-08-05
EP2684874A1 (en) 2014-01-15
HK1147748A1 (en) 2011-08-19
CL2007003049A1 (es) 2008-05-16
WO2008051547A1 (en) 2008-05-02
ES2633318T3 (es) 2017-09-20
JP2010507665A (ja) 2010-03-11
IL198150A (en) 2014-06-30
US20120165519A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
TW200833686A (en) Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
TW200612936A (en) Indole derivatives
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
NZ591166A (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
MX2009012595A (es) Derivados de espiroindolinona.
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
TW200637817A (en) 5-aminoindole derivatives
TW200738651A (en) Cyclohexyl sulfonamide derivatives
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
GB0513886D0 (en) Novel compounds
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives

Legal Events

Date Code Title Description
FG Grant or registration